Replimune Group Dividend
Dividend criteria checks 0/6
Replimune Group no tiene antecedentes de pago de dividendos.
Key information
n/a
Dividend yield
n/a
Payout ratio
Industry average yield | 2.8% |
Next dividend pay date | n/a |
Ex dividend date | n/a |
Dividend per share | n/a |
Earnings per share | -US$3.42 |
Dividend yield forecast in 3Y | n/a |
Recent dividend updates
No updates
Recent updates
Replimune Group (NASDAQ:REPL) Has Debt But No Earnings; Should You Worry?
Feb 06Replimune: The Fall Is Justified, As Virus Therapy Fails Again In Cancer
Jan 23Calculating The Intrinsic Value Of Replimune Group, Inc. (NASDAQ:REPL)
Dec 25Is Replimune Group (NASDAQ:REPL) A Risky Investment?
Jul 13Is Replimune Group (NASDAQ:REPL) Using Debt In A Risky Way?
Apr 05A Look At The Fair Value Of Replimune Group, Inc. (NASDAQ:REPL)
Jan 06Replimune secures $200M term loan
Oct 07Replimune: Recent Developments Strengthen Bull Thesis
Aug 12Replimune Group (NASDAQ:REPL) Has Debt But No Earnings; Should You Worry?
Aug 06Replimune Group GAAP EPS of -$0.78 misses by $0.15
Aug 04Replimune Group, Inc. (NASDAQ:REPL) Shares Could Be 23% Below Their Intrinsic Value Estimate
Jun 24We're Not Very Worried About Replimune Group's (NASDAQ:REPL) Cash Burn Rate
Apr 04Companies Like Replimune Group (NASDAQ:REPL) Are In A Position To Invest In Growth
Dec 16Replimune: In The 'Buy Zone' Again
Oct 01Estimating The Fair Value Of Replimune Group, Inc. (NASDAQ:REPL)
Sep 02Replimune Group (NASDAQ:REPL) Is In A Strong Position To Grow Its Business
May 24Replimune: Oncolytic Immunotherapy Pioneer Gaining Momentum In The Clinic
Apr 30We're Interested To See How Replimune Group (NASDAQ:REPL) Uses Its Cash Hoard To Grow
Feb 08Replimune Group EPS misses by $0.03
Feb 04Dosing underway in Replimune's early-stage cancer study with gene therapy
Jan 05Replimune: Interesting Developer Of Oncolytic Immunotherapies
Dec 06Replimune Group EPS misses by $0.02
Nov 05Stability and Growth of Payments
Fetching dividends data
Dividendo estable: No hay datos suficientes para determinar si los dividendos por acción de REPL han sido estables en el pasado.
Dividendo creciente: Datos insuficientes para determinar si los pagos de dividendos de REPL han aumentado.
Dividend Yield vs Market
Replimune Group Dividend Yield vs Market |
---|
Segment | Dividend Yield |
---|---|
Company (REPL) | n/a |
Market Bottom 25% (US) | 1.5% |
Market Top 25% (US) | 4.7% |
Industry Average (Biotechs) | 2.8% |
Analyst forecast in 3 Years (REPL) | n/a |
Dividendo destacado: No es posible evaluar la rentabilidad por dividendo de REPL en comparación con el 25% inferior de los pagadores de dividendos, ya que la empresa no ha comunicado ningún pago reciente.
Alto dividendo: No es posible evaluar la rentabilidad por dividendo de REPL en comparación con el 25% de los principales pagadores de dividendos, ya que la empresa no ha comunicado ningún pago reciente.
Earnings Payout to Shareholders
Cobertura de los beneficios: No hay datos suficientes para calcular el ratio de reparto de REPL para determinar si sus dividendos están cubiertos por los beneficios.
Cash Payout to Shareholders
Cobertura de flujo de caja: No es posible calcular la sostenibilidad de los dividendos, ya que REPL no ha comunicado ningún pago.